A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia
Latest Information Update: 12 Dec 2022
At a glance
- Drugs Alirocumab (Primary) ; Ezetimibe
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms ODYSSEY MONO; ODYSSEY-Mono
- Sponsors Sanofi
- 05 Sep 2018 Results of pooled data from 14 trials, were published in the Diabetic Medicine.
- 15 Nov 2017 Results of pooled analysis from ten ODYSSEY trials assessing characteristics of patients with less than 5% LDL-C reduction presented at the 90th Annual Scientific Sessions of the American Heart Association
- 11 Aug 2017 Results (n=3341) of a pooled post-hoc analysis from ten ODYSSEY Phase 3 (LONG TERM, HIGH FH, COMBO I, FH I, FH II, COMBO II, OPTIONS I, OPTIONS II, MONO and ALTERNATIVE) trials, published in the Diabetic Medicine.